NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence submission was received from Amgen. The company has confirmed that it does not intend to make a submission because denosumab is unlikely to be used at this point in the treatment pathway.
If NHS organisations wish to consider denosumab for preventing skeletal-related events in multiple myeloma, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.
NICE will review the position if the company decides that it wants to make an evidence submission.